These include ICIs to restore CD8+ T-cell function, tumor vaccines to enhance antigen presentation, adoptive transfer of tumor-infiltrating lymphocytes (TILs) or T cells with engineered TCRs, chimeric antigen receptor (CAR)-modified T cells, bispecific antibodies (bsAbs), and strategies to modulate the tumor immune microenvironment [28,29,30]. The gene discussed is CD8A; the disease is neoplasm.